Zhao Yunchun, Zheng Xiaoling, Zheng Yongquan, Chen Yue, Fei Weidong, Wang Fengmei, Zheng Caihong
Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Key Lab Women's Reproductive Health, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Oncol. 2021 Apr 22;11:650453. doi: 10.3389/fonc.2021.650453. eCollection 2021.
Increasing evidence shows that the extracellular matrix (ECM) is an important regulator of breast cancer (BC). The ECM comprises of highly variable and dynamic components. Compared with normal breast tissue under homeostasis, the ECM undergoes many changes in composition and organization during BC progression. Induced ECM proteins, including fibrinogen, fibronectin, hyaluronic acid, and matricellular proteins, have been identified as important components of BC metastatic cells in recent years. These proteins play major roles in BC progression, invasion, and metastasis. Importantly, several specific ECM molecules, receptors, and remodeling enzymes are involved in promoting resistance to therapeutic intervention. Additional analysis of these ECM proteins and their downstream signaling pathways may reveal promising therapeutic targets against BC. These potential drug targets may be combined with new nanoparticle technologies. This review summarizes recent advances in functional nanoparticles that target the ECM to treat BC. Accurate nanomaterials may offer a new approach to BC treatment.
越来越多的证据表明，细胞外基质（ECM）是乳腺癌（BC）的重要调节因子。细胞外基质由高度可变且动态的成分组成。与处于稳态的正常乳腺组织相比，细胞外基质在乳腺癌进展过程中会发生许多成分和组织结构的变化。近年来，包括纤维蛋白原、纤连蛋白、透明质酸和基质细胞蛋白在内的诱导型细胞外基质蛋白已被确定为乳腺癌转移细胞的重要组成部分。这些蛋白质在乳腺癌进展、侵袭和转移中起主要作用。重要的是，几种特定的细胞外基质分子、受体和重塑酶参与促进对治疗干预的抗性。对这些细胞外基质蛋白及其下游信号通路的进一步分析可能会揭示有前景的抗乳腺癌治疗靶点。这些潜在的药物靶点可与新的纳米颗粒技术相结合。本综述总结了靶向细胞外基质治疗乳腺癌的功能性纳米颗粒的最新进展。精确的纳米材料可能为乳腺癌治疗提供一种新方法。
